Trials / Recruiting
RecruitingNCT06029257
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech Republic
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab | As provided in real-world clinical practice. |
Timeline
- Start date
- 2023-11-14
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2023-09-08
- Last updated
- 2025-01-29
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT06029257. Inclusion in this directory is not an endorsement.